GlassScriptPhysician profile
Gregory A Carico
NPI 1962439885
$9,068.99
in general payments reported to CMS, 2019-2025
50 companies · $55.26 in 2025
The $55.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,586 · 2020: $1,392 · 2021: $1,413 · 2022: $1,542 · 2023: $1,587 · 2024: $493 · 2025: $55.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Education: $71.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.34 |
| Education | $71.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $970.71 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $947.81 | 2019-2024 | Farxiga, Lokelma, Breztri |
| Abbvie INC. | $937.11 | 2021-2024 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $815.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $680.24 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $579.37 | 2019-2025 | Evenity, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $562.65 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $377.73 | 2019-2024 | Freestyle Libre 3 |
| Pfizer INC. | $325.99 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $315.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.19 | 2019-2021 | |
| Lilly USA, LLC | $255.45 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $162.12 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.13 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $154.36 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Carico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.